Table 1

Variables at baseline, pre-propensity and post-propensity score matching for patients with ≥5 years of follow-up from pooled LTE and Toronto Lupus Cohort datasets

Variable	Pre-propensity score matching (n=973)			Post-propensity score matching (n=362)
	Mean		% Bias	Mean		% Bias
	Belimumab	Standard therapy	% Bias	Belimumab	Standard therapy	% Bias
Age	39.674	37.336	19.3	39.337	39.105	1.9
Age squared	1693.9	1565.8	12.8	1691.8	1685.5	0.6
Female	0.927	0.895	11.4	0.895	0.906	−3.7
Race
Black	0.091	0.150	−18.0	0.116	0.133	−5.0
Asian/other	0.471	0.234	51.3	0.315	0.331	−3.5
SLE duration	6.683	5.738	13.9	7.044	6.946	1.3
Hypertension	0.426	0.370	11.4	0.403	0.409	−1.1
Dyslipidaemia	0.132	0.570	−103.1	0.326	0.309	3.6
Proteinuria	0.167	0.312	−34.4	0.210	0.204	1.4
ACR criteria	5.932	5.646	20.8	5.856	5.823	2.5
Baseline SLEDAI	8.027	10.016	−42.5	9.094	8.912	4.4
Corticosteroid use	0.843	0.606	54.9	0.707	0.713	−1.2
Antimalarial use	0.698	0.522	36.5	0.669	0.597	14.9
Immunosuppressive use	0.458	0.310	30.8	0.431	0.392	7.8
Baseline SDI=1	0.233	0.150	21.3	0.204	0.193	2.8
Baseline SDI≥2	0.181	0.105	21.8	0.177	0.160	4.4

ACR, American College of Rheumatology; LTE, long-term extension; SDI, SLICC/ACR Damage Index; SLE, systemic lupus erythamatosus; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SLICC, Systemic Lupus International Collaborating Clinics.